scholarly journals The effectiveness of liposomal doxorubicin hydrochloride in combination with cyclophosphan in the treatment of breast cancer in an experiment

2021 ◽  
Vol 8 (4) ◽  
pp. 23-32
Author(s):  
L. A. Balykova ◽  
V. I. Inchina ◽  
T. V. Tarasova ◽  
L. M. Mosina ◽  
E. N. Gvozdikova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Liposomal Doxorubicin ◽  
Tumor Regression ◽  
Lung Metastases ◽  
Control Group ◽  
Doxorubicin Hydrochloride ◽  
Liposomal Form ◽  
White Rats ◽  
Walker 256

Purpose of the study. To evaluate the antitumor efficacy of liposomal doxorubicin hydrochloride in combination with tamoxifen in the treatment of breast cancer.Materials and methods. The study included mongrel white rats (n = 30). A model of carcinogenesis (Walker 256 tumors) was created for all animals. Then we divided these rats into 3 equal groups: 1 control group (n = 10) - animals were monitored without treatment; 2 group (n = 10) - animals received neoadjuvant therapy: liposomal doxorubicin hydrochloride + cyclophosphan; 3 group (n = 10) - animals received neoadjuvant therapy with doxorubicin hydrochloride (non-liposomal) and cyclophosphan. Animals of the second and third groups received two cycles of neoadjuvant therapy. All animals were monitored for 1.5 months. We evaluated the effectiveness of antitumor therapy by measuring the size of tumors, the dynamics of their regression, and counting the number of metastases in the lungs. The toxic effects of doxorubicin hydrochloride were assessed by blood parameters: platelet and lymphocyte levels.Results. We recorded a significant inhibition of the growth of tumor nodes in the second group of rats on the 25th day from the start of the experiment compared with the first and third groups: 36004.7, 86112.1 and 38962.4 mm3, respectively. By the end of the 3rd week of the experiment, we also noted the formation of a tumor regression trend in the 2nd and 3rd groups of animals, which was reliably maintained until the end of the observation. At the end of the experiment, the number of metastases in the first group of animals was 3 times more, in the third group almost 1.5 times more than in the second (p < 0.05)Conclusion. The treatment of Walker 256 tumor with liposomal doxorubicin showed better efficacy and safety in comparison with non-liposomal doxorubicin. The tumor volume becomes smaller against the background of neoadjuvant chemotherapy with liposomal doxorubicin hydrochloride compared with its non-liposomal form, while there is no pronounced decrease in platelets and lymphocytes. We also recorded a significantly lower number of lung metastases in animals of the second group compared to other groups.

scholarly journals Examination of Tumor Regression Grading Systems in Breast Cancer Patients Who Received Neoadjuvant Therapy

2020 ◽  
Vol 26 (4) ◽  
pp. 2747-2754
Author(s):  
Anita Sejben ◽  
Renáta Kószó ◽  
Zsuzsanna Kahán ◽  
Gábor Cserni ◽  
Tamás Zombori
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Cancer Patients ◽  
Tumor Regression ◽  
Breast Cancer Patients ◽  
Regression Grading ◽  
Grading Systems

THE EFFECT OF CYTOSTATIC DRUGS ON THROMBOCYTOPOIESIS IN RATS WITH WALKER-256 CARCINOMA

2021 ◽  
pp. 4-11
Author(s):  
Balykova L.A. ◽  
Siprov A.V. ◽  
Inchina V.I. ◽  
Tarasova T.V. ◽  
Mosina L.M. ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Rapid Development ◽  
Free Form ◽  
Malignant Neoplasms ◽  
Cytostatic Drugs ◽  
Liposomal Form ◽  
Treatment And Prevention ◽  
Search Field ◽  
Walker 256 ◽  
Ethylmethylhydroxypyridine Succinate

Among malignant neoplasms of women, breast cancer (BC) takes the leading place and is the cause of high mortality and complications. Side effects in the form of anemia, thrombocytopenia, bleeding, etc. often develop during cytostatic therapy, which is the main method of treatment and prevention of further development of the oncological process. In this regard, the problem of reducing side metabolic disorders remains relevant and creates a search field for the use of drugs aimed at stabilizing functions, both at the cellular and organ levels. The aim of the study was to evaluate the effect of cytostatic drugs on thrombocytopoiesis in rats with WALKER-256 carcinoma. The study included 60 rats, which, depending on the type of treatment, were divided into 5 groups. A week after the start of chemotherapy, the greatest increase in the number of platelets was in the presence of liposomal ethylmethylhydroxypyridine succinate. We recorded that the myeloprotective effect was 1/3 better in liposomal ethylmethylhydroxypyridine succinate compared to its non-liposomal form. Therefore, individuals those receiving cytostatic drugs in the treatment of breast cancer need protection from myelopoiesis. In the studies carried out by us, it was shown that oxidative stress occurred in animals against the background of treatment with cytostatics. It was its rapid development that caused damage to the platelet cell membranes. In this regard, we have proposed a drug with a pronounced antioxidant efficacy. The introduction of an antioxidant into the generally accepted standard treatment of a tumor process has made it possible to experimentally select methods for delivering the drug to the targets of damage using liposomal forms. The study obtained data proving the effectiveness of the use of liposomal ethylmethylhydroxypyridine succinate (50 mg / kg), in contrast to its free form, which prevents the development of thrombocytopenia induced by the administration of cytostatic drugs to rats with Walker-256 carcinoma.

Safety and efficacy of a phase I/IIa trial (NCT03066947) of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e14026-e14026
Author(s):  
William Williams ◽  
Jarrod P. Holmes ◽  
Saveri Bhattacharya ◽  
Carmen Calfa ◽  
Shaker R. Dakhil ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tumor Regression ◽  
Lung Metastases ◽  
Cell Activity ◽  
Metastatic Breast ◽  
Cancer Cell Line ◽  
Hla Class I ◽  
Tumor Stage ◽  
Interferon Α ◽  
Gm Csf

e14026 Background: SV-BR-1-GM is a GM-CSF transfected breast cancer cell line which expresses HLA class I & II antigens and has functional antigen-presenting cell activity. Prior studies suggest that partial matching of the HLA type of the patient with SV-BR-1-GM may be predictive of tumor regression. Methods: Subjects received low-dose cyclophosphamide 2-3d prior to ID injection of irradiated SV-BR-1-GM (20 million cells divided into 4 sites) and interferon-α into the inoculation sites ~2 & 4 days subsequently. Cycles were q2 weeks x 3 then q mo. Results: A total of 30 patients were screened and 23 inoculated (Table). The patients were heavily pretreated with a median of 4 prior chemo/biological therapy regimens. There were no serious or unexpected adverse events. Local injection-site irritation was the most common toxicity. Objective tumor regression was seen in 3 patients, all of whom matched SV-BR-1-GM at least at one HLA locus: one patient with regression or clearing of 20 lung metastases; one with reduction in cutaneous involvement of the breast from 80% to 30% and one with regression of a breast lesion. Another 3 patients had decreases in circulating cancer-associated macrophage-like cells (CAMLs), which has been shown to correlate with tumor stage. They also all matched at least at one HLA allele. Circulating tumor cells and circulating epithelial cells were present in low numbers and tended to parallel trends in CAMLs which were present in larger numbers. CAMLs in 21/23 patients stained positive for PD-L1. Patients with tumor regression had robust DTH responses to SV-BR-1-GM. Conclusions: SV-BR-1-GM in this regimen appears to be safe and well-tolerated and is associated with objective regression of metastatic breast cancer and/or with decreases in circulating cancer-associated cells in 6/23 (26%) or patients. HLA matching may be a predictor of response. Clinical trial information: NCT03066947. [Table: see text]

Cardiac safety and efficacy of concomitant liposomal doxorubicin, docetaxel, and trastuzumab as neoadjuvant therapy in HER2-overexpressing breast cancer: A retrospective analysis.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 583-583
Author(s):  
Christine Brunner ◽  
Thomas Jaeger ◽  
Christoph Suppan ◽  
Elisabeth Mueller-Holzner ◽  
Zerina Jasarevic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Therapy ◽  
Liposomal Doxorubicin ◽  
Pathological Complete Response ◽  
Neoadjuvant Treatment ◽  
Complete Response ◽  
Left Ventricular Ejection ◽  
Cardiac Safety ◽  
Multicenter Analysis

583 Background: Concurrent therapy of trastuzumab, anthracycline and taxane for the neoadjuvant treatment of breast cancer (BC) results in an improved rate of pathological complete response (pCR). However, there is considerable concern about the cardiac safety of this combination. The use of liposomal doxorubicin might be a valuable alternative with lower cardiotoxicity. We report cardiac safety and pCR-rate of a single arm, retrospective, multicenter analysis of neoadjuvant treatment for BC with liposomal doxorubicin, trastuzumab, and docetaxel. Methods: In this study 84 women with BC and HER2 overexpression were investigated in 3 oncological departments in Austria. All patients were treated with liposomal doxorubicin (50 - 60 mg/m²), docetaxel (75 mg/m²) and concurrent with trastuzumab for 6 cycles as neoadjuvant therapy. All patients were free of cardiovascular disease and had a left ventricular ejection fraction (LVEF) of ≥ 55%. Cardiac function was by LVEF and was examined at regular intervals(cycles 0-3, cycle 6, FU). Clinical response was evaluated by diagnostic breast imaging after cycles 3 and 6. All patients underwent surgery after neoadjuvant chemotherapy. The absence of any residual invasive cancer in the breast and axilla was defined as pathological complete response (pCR). Median follow up was 2.4 years. Results: Median age of the patients was 50 years. After 6 cycles of treatment the pCR rate was 46%. In this cohort a negative estrogen-and/or progesteron receptor was predictive for pCR (p<0.001). No patient progressed during treatment. None of the patients suffered symptomatic heart failure. Only one patient (1.6%) with asymptomatic LVEF of 45% was observed during follow-up. Conclusions: In this multicenter analysis we observed a considerably high rate of pCR in HER2-positive BC treated with liposomal doxorubicin, docetaxel and trastuzumab. The addition of liposomal doxorubicin instead of conventional doxorubicin or epirubicin entails a very favorable cardiotoxicity profile. This regimen is a safe treatment option in patients with HER-2 positive breast cancer.

Psoralen-loaded polymeric lipid nanoparticles combined with paclitaxel for the treatment of triple-negative breast cancer

Nanomedicine ◽  
2021 ◽  
Author(s):  
Fengjie Liu ◽  
Lihong Li ◽  
Meng Lan ◽  
Tengteng Zou ◽  
Zhaodi Kong ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Lung Metastases ◽  
Lipid Nanoparticles ◽  
Significant Inhibition ◽  
Control Group ◽  
Breast Cancer Patients ◽  
Combined Administration ◽  
Inhibition Of Tumor Growth

Background: Chemotherapeutic drugs are associated with toxic effects. Metastasis is the leading cause of death in breast cancer patients. Aim: To evaluate the antitumor effect of paclitaxel (PTX) combined with psoralen-loaded polymeric lipid nanoparticles (PSO-PLNs) in triple-negative breast cancer. Methods: After treatment of samples, cell viability, apoptosis, migration, invasion, expression of proteins in the IRAK1/NF-κB/FAK signal pathway, biodistribution and pathological characteristics were detected. Results: Compared with the control group, the PTX + PSO-PLNs group showed increased apoptosis and reduced migration, invasion and expression of phosphorylated IRAK1 and NF-κB, with significant inhibition of tumor growth and lung metastases and no obvious toxicity. Conclusion: Combined administration of PTX and PSO-PLNs exerted a synergistic effect and significantly inhibited the growth and metastasis of triple-negative breast cancer.

scholarly journals Combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer with axillary lymph node metastasis

2020 ◽  
Vol 48 (8) ◽  
pp. 030006052094431
Author(s):  
Li Wang ◽  
Yang Hong ◽  
Jie Ma ◽  
Meng Han ◽  
Shuo Zhang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Neoadjuvant Therapy ◽  
Axillary Lymph Node ◽  
Liposomal Doxorubicin ◽  
Pegylated Liposomal Doxorubicin ◽  
Axillary Lymph Node Metastasis ◽  
Axillary Lymph ◽  
Node Metastasis

Objective To evaluate the efficacy and safety of the combination of pegylated liposomal doxorubicin and docetaxel as neoadjuvant therapy for breast cancer (BC) in patients with axillary lymph node metastasis. Methods In this single-arm study, 91 patients with clinical stage IIA–IIIc breast cancer received six cycles of pegylated liposomal doxorubicin plus docetaxel as neoadjuvant chemotherapy (NAC). Trastuzumab was allowed for patients with human epidermal growth factor receptor 2-positive tumors. The primary endpoint was pathologic complete response (pCR) in the breast after surgery. The overall response rate (ORR), Miller–Payne (MP) score of the primary tumors, and incidence of adverse events were also evaluated. Results In total, 88 patients completed all cycles of NAC. Fourteen patients (15.4%, 95% confidence interval [CI] = 7.8–22.9) achieved pCR. The ORR was 89% (95% CI = 82.5–95.6), and 72 lesions (79.1%) were rated as MP grade 3 or higher. The left ventricular ejection fraction (LVEF) was within the normal range, although four (4.4%) patients experienced an LVEF decline exceeding 10%. No symptomatic cardiac events were reported. Conclusion Preoperative NAC with pegylated liposomal doxorubicin and docetaxel appears effective and safe for treating BC with axillary lymph node metastasis.

scholarly journals EVALUATION OF THE SYSTEMIC AND REGIONAL ANTIBIOTIC THERAPY EFFECTIVENESS AS PART OF COMPLEX THERAPY IN PATIENTS WITH LOCALLY SPREAD BREAST CANCER

2019 ◽  
Vol 2 ◽  
pp. 19-25
Author(s):  
Oleksandr Bondar
Keyword(s):  
Breast Cancer ◽  
Antibiotic Therapy ◽  
Neoadjuvant Therapy ◽  
Developed Countries ◽  
Psychological State ◽  
Long Term Results ◽  
Control Group ◽  
Regional Administration ◽  
Inflammatory Changes

In recent years, breast cancer is the most common oncologic pathology and the most common cause of disability among women in developed countries. The aim of the study. To improve direct and long-term results of treatment in patients with locally spread forms of breast cancer (LSBC) by accelerated regression of perifocal inflammatory changes using selective intraarterial application of antibiotics; improving patients’ quality of life. Materials and methods. The main sample consisted of 109 patients.The control group included 65 (61 %) clinical cases of LSBC who were performed series of courses of intravenous systemic polychemotherapy (SPHT) as neoadjuvant therapy accompanied by systemic intravenous antibiotic therapy. The study group consisted of 42 (39 %) patients who were performed selective intraarterial neoadjuvant polychemotherapy course with simultaneous regional use of antibiotic therapy in the intraarterial administration. Results. The regional administration of antibiotics as a part of the complex neoadjuvant therapy, along with the method of selective intraarterial polychemotherapy, has a positive effect on the linear and chronometric regression of perifocal inflammatory changes around the focus of the primary inoperable LSBC, which positively affects the somatic and psychological patient's state and increases the quality of his life. Conclusions. The complex regional impact on the affected organ has a statistically confirmed better effect with bright holistic features, demonstrating the additive synergism of selective techniques.The selective intraarterial antibiotic therapy does not require additional time and material costs while increasing the efficiency of the method. The versatile advanced approach positively affects the somatic and psychological state of the patient.

scholarly journals Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Weifang Liu ◽  
Wei Chen ◽  
Xiuxiang Zhang ◽  
Peng Zhao ◽  
Zhimin Fan ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Adverse Reactions ◽  
Liposomal Doxorubicin ◽  
Molecular Subtype ◽  
Pathologic Complete Response ◽  
Pegylated Liposomal Doxorubicin ◽  
Control Group ◽  
Observation Group ◽  
Cardiac Side Effects

AbstractThe present study aimed to investigate the efficacy and toxicity of pegylated liposomal doxorubicin (PLD) in preoperative neoadjuvant chemotherapy for patients with breast cancer by comparing with conventional anthracycline. This study is a non-randomized controlled trial. Prospective analysis was conducted after matching as required. A total of 146 patients with confirmed diagnosis of breast cancer by histopathological examinations were enrolled into the observation group and control group in 1:1 ratio. Each of the cases in the observation group was required to correspond to another in the control group according to the requirements including age, molecular subtype, axillary node status, and regimen of the preoperative neoadjuvant chemotherapy. The chemotherapy was based on regimens consisting of anthracyclines, paclitaxel or docetaxel, and/or platinum. PLD was used at least twice in the observation group, with traditional anthracycline as a contrast in the control group. Clinical responses as well as cardiac side effects and other adverse reactions were evaluated by clinical and imaging examinations such as electrocardiogram (ECG) and color Doppler ultrasound during the chemotherapy. Pathologic examinations were performed following the surgeries after preoperative neoadjuvant chemotherapy. All the patients in both groups completed the preoperative neoadjuvant chemotherapy according to their original regimens. The postoperative pathological evaluation revealed a higher pathologic complete response (PCR) rate and significantly more patients of grade V of the Miller-Payne grading system in the observation group as compared to the control group (p = 0.047). In addition, the observation group recorded an evidently lower occurrence of the adverse cardiac events (p = 0.014), ECG changes (p = 0.048), and the relatively severe adverse reactions such as myelosuppression. Compared with conventional anthracycline drugs, PLD has a better pathologic response and safety performance, as well as a similar clinical effectiveness in preoperative neoadjuvant chemotherapy for breast cancer.

Sign in / Sign up

Export Citation Format

Share Document